235423-04-8

Basic information

• Product Name: 4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran
• CAS NO: 235423-04-8
• Molecular Weight: 177.246
• Mol File: 235423-04-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran(235423-04-8)
• EPA Substance Registry System: 4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran(235423-04-8)

Safety Data

• Hazardous Substances Data: 235423-04-8(Hazardous Substances Data)

Upstream product

• 24700-17-2 3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-hydroxyimine 
• 3780-33-4 2,3-dihydro-2,2-dimethylbenzo[b]pyran-4-one 
• 1072930-94-9 4-azido-2,2-dimethyl-3,4-dihydro-2H-chromene 

Downstream Products

• 1144501-46-1 (R)-2-hydroxy-2-phenylacetate salt of (R)-2,2-dimethylchroman-4-amine 

Relevant articles and documents

TRPV1 Antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Synthesis and activity on rat aorta rings and rat pancreatic β-cells of ring-opened analogues of benzopyran-type potassium channel activators

Ring-opened analogues of dihydrobenzopyran potassium channel openers (PCOs) were prepared and evaluated as putative PCOs on rat aorta rings (myorelaxant effect) and rat pancreatic β-cells (inhibition of insulin secretion). These derivatives are characterized by the presence of a sulfonylurea, a urea or an amide function. Some compounds bearing an arylurea moiety provoked vasorelaxant effects and a marked inhibition of insulin release. Derivatives bearing a sulfonylurea or an amide function were, however, poorly active on both tissues. Structure-activity relationships and apparent tissue selectivity are discussed.

PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).